A higher risk of adult psychotic experiences is associated with childhood cat ownership.

Published Date: 24 Apr 2023

Canada: The Journal of Psychiatric Research recently reported that childhood cat ownership, particularly with rodent-hunting cats,.

Read Full News

Latest News

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

6 Psychiatry Headlines You Missed in January 2026

6 Psychiatry Headlines You Missed in January 2026

FDA Examines Generative AI in Psychiatry, With Hans Eriksson, MD, PhD Hans Eriksson, MD, PhD

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

Utilizing Alcohol Use Disorder Pharmacotherapy in Hepatology, With Hersh Shroff, MD, MPA Hersh Shroff, MD, MPA

Shroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care Lisa A. Swanson, MD, Enzo Berardesca, MD, Mohammad Jafferany, MD

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

Todays Updates

Novel Psychedelic Promising on Resistant Depression

An investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.

Biocomputer From Human Neurons Plays Doom, Raises Ethics

A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.

EMA OKs Two Treatments for Small Cell Lung Cancer

Both drugs increase overall and progression-free survival.

Todays Updates

Novel Psychedelic Promising on Resistant Depression

An investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.

Biocomputer From Human Neurons Plays Doom, Raises Ethics

A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.

EMA OKs Two Treatments for Small Cell Lung Cancer

Both drugs increase overall and progression-free survival.

Latest News

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

6 Psychiatry Headlines You Missed in January 2026

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

Shroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

News All Time

Psychiatry in 2025: Year in Review

Psychiatry in 2025: Year in Review

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

4 Psychiatry Headlines You Missed in November 2025

4 Psychiatry Headlines You Missed in November 2025

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Single Dose of MM120 (LSD) Shows Lasting Anxiety Reduction in GAD: Phase 2b Results Chelsie Derman

A phase 2b trial finds a single 100 μg dose of MM120 reduced GAD symptoms with benefits lasting 12 weeks, highlighting the promise of psychedelic therapy.

FDA Releases CRL Detailing Safety Concerns for MDMA-Assisted Therapy in PTSD Chelsie Derman

MDMA’s CRL, now available to the public, cites gaps in safety data, selection bias, and limited durability.

Prenatal Opioid Pain Medications Likely Not Linked to Autism or ADHD Risk Chelsie Derman

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

Atopic Eczema Linked to Suicidal Ideation in Global Study of 30,000 Adults Chelsie Derman

EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.

FDA Initiates Acetaminophen Label Change, Leucovorin Approval for Cerebral Folate Deficiency Abigail Brooks, MA

The Agency initiated an acetaminophen label change to reflect evidence of potential harms in pregnant women and an approval of leucovorin for CFD.

Daily Ammoxetine at 40, 60 mg Outperforms Placebo for MDD in Phase 2 Trial Chelsie Derman

A phase 2 trial demonstrated the effectiveness, safety, and tolerability of ammoxetine (40 and 60 mg) in patients with major depressive disorder.

APhA, Coalition of Autism Scientists Cite Insufficient Data to Support Acetaminophen, Autism Link Abigail Brooks, MA

Both organizations defend the use of Tylenol during pregnancy, citing “rigorous” and “reputable” research suggesting it does not cause autism in children.

5 Psychiatry Headlines You Missed in September 2025 Chelsie Derman

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

Recommended News For You

The Early Progression of Prostate Cancer Is Not Stopped by Metformin.

healthy despite having advanced cancer.

How cancer misinformation exploits the way we think

Weight loss and cancer; no brain tumor blood test; no cervical cancer after HPV vaccination.

Higher Binge Drinking Rates Linked to New Cannabis Laws.

Is Exercise an Effective Treatment for Prostate Cancer?

Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap

Recommended Articles For You

Exploring the Unseen: Carcinoid Syndrome and its Impact on Quality of Life 

The Statistical Paradigm of Leukemia: From Evolving Epidemiology and Molecular Stratification to Precision Therapies and Future Horizons in Leukemia 

How is Digital Innovation Revolutionizing Gynecologic Oncology Treatment and Patient Engagement? 

Next-Gen CAR Cell Therapies in Oncology: Frontiers in Solid Tumors & Hematologic Malignancies 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

AI can identify women at risk of breast cancer years in advance: Study

2.

Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.

3.

An inoperable locally advanced NSCLC trial dubbed "Practice Changing".

4.

First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.

5.

Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC

1.

Ethics of Experimental Oncology: Case Study on Autonomy, Consent & Decision-Making

2.

Beyond the Surface: Understanding the Silent Menace of Abdominal Hematomas

3.

Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients

4.

A Mural of Thrombus: Unlocking the Power of Art to Combat Cardiovascular Disease

5.

Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V

2.

Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

5.

CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot